Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Otsuka

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Otsuka's 2012 sales performance.

Otsuka

Takeda grows in Turkey with Neutec subsidiary acquisition

Takeda grows in Turkey with Neutec subsidiary acquisition Other companies investing in Turkey of late include Amgen - which bought local producer Mustafa Nevzat in 2012 for $700m - while Sanofi, Otsuka and Recordati are among companies building manufacturing capacity in

J&J gets quicker review for schizophrenia depot in US

J&J gets quicker review for schizophrenia depot in US in the summer, as well as two novel antipsychotics - Otsuka/Lundbeck's brexpiprazole and cariprazine from Actavis and Gedeon Richter.

Deal Watch table for December 2014

Deal Watch table for December 2014 Company acquisition. 9, 500. Avanir Pharmaceuticals / Otsuka Pharmaceutical. Portfolio of CNS products, inc Nuedexta marketed for pseudobulbar affect. ... Research collaboration, options to license. 125. ††Ariad Pharmaceuticals / Otsuka Pharmaceutical

Pharma deals during December 2014

Pharma deals during December 2014 Also on the acquisition trail were Otsuka and Roche buying into CNS products for diseases with high unmet need and bispecific antibody technology, respectively.

Patent cliff losses set to cost pharma $65bn by 2019

Patent cliff losses set to cost pharma $65bn by 2019 Lilly, AZ and Otsuka to be hit hard, says GlobalData. Pharma firms should brace themselves for an estimated $65bn drop in sales by 2019 due to patent expiries on several leading ... Research and consulting company GlobalData says a significant proportion

[ Previous 5 results ] 9 10 11 12 13 14 15 16 17 18 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ahair@onyxhealth.com

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...